Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq leads Wall St higher as Nvidia eases AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil prices rise as investors weigh lack of progress in Middle East negotiations
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Pacira Pharmaceuticals (PCRX) PT Lowered to $52 at Jefferies
November 9, 2017 8:29 AM ESTJefferies lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $52.00 (from $57.00) while maintaining a Buy rating following results.
Analyst David Steinberg trimmed FY17 Exparel revs by $8M to $283M to align with the midpoint of updated guidance.They also trim FY18-20 sales ests by 4-6%
... More